Shire reported third-quarter 2014 earnings (excluding special items
and amortization) of $2.93 per ADS, up from $1.83 per ADS in the
year-ago quarter and beating the Zacks Consensus Estimate of $2.47.
Quarterly revenues increased 31.7% to $1.6 billion, beating the
Zacks Consensus Estimate of $1.5 billion. The increase in revenues
was driven by growth in the Rare Diseases business unit. We are
encouraged by the company's third-quarter results. The subsequent
increase in guidance is encouraging as well. With AbbVie
terminating its acquisition offer in Oct 2014, we expect Shire to
focus on its existing drugs and pipeline. We believe the company's
efforts to build a leaner organization with focus on rare diseases
should lead to improved margins.
Founded in 1986, Dublin-based Shire is a specialty
biopharmaceutical company catering to diverse medical needs through
research and development, manufacture, sale and distribution of
Shire repositioned its business in 2013, undertaking a
realignment program with strategic focus on rare diseases and
greater operational discipline. With an aim to reduce overlap,
Shire has merged its three autonomous divisions into one. Shire
realigned its business structure to drive growth and innovation. As
per the strategy, Shire has an "In-Line" marketed product group and
a Pipeline Group, with centralized corporate functions. The In-Line
marketed products group consist of five business lines, which will
focus on commercial delivery Rare Diseases, Neuroscience (formerly
Behavioral Health), Gastrointestinal (GI), Regenerative Medicine
(RM) and Internal Medicine (with a focus on Adderall XR, Fosrenol
and Xagrid) . The Pipeline Group consists of Research &
Development (R&D) and Business Development (BD). The unit
focuses on late-stage development programs with pre-clinical
development focus being primarily on rare diseases, led by a single
R&D organization. The BD unit focuses on identifying
later-stage development programs and in-market products in target
specialist areas. Further, Shire will expand its footprint in Asia
and Latin America with a key focus on Japan, China and Brazil.
For 2013, the company reported revenues of $4.9 billion, up 9%
year over year. Product sales of $4.7 billion were up 12% from
2012. Shire also receives royalty revenues which mainly comprise
income earned from the sale of the authorized generic version of
Adderall XR, 3TC, Zeffix, Fosrenol and others. Income from
royalties came in at $153.7 million, down 36% from 2012.
Sales in 2013 (in millions of dollars)
Attention deficit and hyperactivity disorder (ADHD)
Hyperphosphatemia in end stage renal disease
hereditary angioedema or HAE
Shire plc (SHPG): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.